Discovery of a potent and selective free fatty acid receptor 1 agonist with low lipophilicity and high oral bioavailability
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Discovery of a potent and selective free fatty acid receptor 1 agonist with low lipophilicity and high oral bioavailability. / Christiansen, Elisabeth; Due-Hansen, Maria E; Urban, Christian; Grundmann, Manuel; Schmidt, Johannes; Hansen, Steffen V F; Hudson, Brian D; Zaibi, Mohamed; Markussen, Stine B; Hagesaether, Ellen; Milligan, Graeme; Cawthorne, Michael A; Kostenis, Evi; Kassack, Matthias U; Ulven, Trond.
I: Journal of Medicinal Chemistry, Bind 56, Nr. 3, 14.02.2013, s. 982-992.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Discovery of a potent and selective free fatty acid receptor 1 agonist with low lipophilicity and high oral bioavailability
AU - Christiansen, Elisabeth
AU - Due-Hansen, Maria E
AU - Urban, Christian
AU - Grundmann, Manuel
AU - Schmidt, Johannes
AU - Hansen, Steffen V F
AU - Hudson, Brian D
AU - Zaibi, Mohamed
AU - Markussen, Stine B
AU - Hagesaether, Ellen
AU - Milligan, Graeme
AU - Cawthorne, Michael A
AU - Kostenis, Evi
AU - Kassack, Matthias U
AU - Ulven, Trond
PY - 2013/2/14
Y1 - 2013/2/14
N2 - The free fatty acid receptor 1 (FFA1, also known as GPR40) mediates enhancement of glucose-stimulated insulin secretion and is emerging as a new target for the treatment of type 2 diabetes. Several FFA1 agonists are known, but the majority of these suffer from high lipophilicity. We have previously reported the FFA1 agonist 3 (TUG-424). We here describe the continued structure-activity exploration and optimization of this compound series, leading to the discovery of the more potent agonist 40, a compound with low lipophilicity, excellent in vitro metabolic stability and permeability, complete oral bioavailability, and appreciable efficacy on glucose tolerance in mice.
AB - The free fatty acid receptor 1 (FFA1, also known as GPR40) mediates enhancement of glucose-stimulated insulin secretion and is emerging as a new target for the treatment of type 2 diabetes. Several FFA1 agonists are known, but the majority of these suffer from high lipophilicity. We have previously reported the FFA1 agonist 3 (TUG-424). We here describe the continued structure-activity exploration and optimization of this compound series, leading to the discovery of the more potent agonist 40, a compound with low lipophilicity, excellent in vitro metabolic stability and permeability, complete oral bioavailability, and appreciable efficacy on glucose tolerance in mice.
KW - Administration, Oral
KW - Animals
KW - Biological Availability
KW - Drug Discovery
KW - Magnetic Resonance Spectroscopy
KW - Mice
KW - Models, Molecular
KW - Receptors, G-Protein-Coupled
KW - Spectrometry, Mass, Electrospray Ionization
KW - Structure-Activity Relationship
U2 - 10.1021/jm301470a
DO - 10.1021/jm301470a
M3 - Journal article
VL - 56
SP - 982
EP - 992
JO - Journal of Medicinal Chemistry
JF - Journal of Medicinal Chemistry
SN - 0022-2623
IS - 3
ER -
ID: 189162297